Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer

References

• Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-Initial work-up and medical management. J Urol. 2021;206(4):806–817.
   PubMed Web of Science ®Google Scholar
• Fiard G, Stavrinides V, Chambers ES, et al. Cellular senescence as a possible link between prostate diseases of the ageing male. Nat Rev Urol. 2021;18(10):597–610.
   PubMed Web of Science ®Google Scholar
• Sarkar P, Malik S, Banerjee A, et al. Differential microbial signature associated with benign prostatic hyperplasia and prostate cancer. Front Cell Infect Microbiol. 2022;12:894777.
   PubMed Web of Science ®Google Scholar
• Iversen P, Roder MA. The early prostate cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther. 2008;8(3):361–369.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–424.
   PubMed Web of Science ®Google Scholar
• Kraehenbuehl L, Weng CH, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37–50.
   PubMed Web of Science ®Google Scholar
• Passaro A, Brahmer J, Antonia S, et al. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J Clin Oncol. 2022;40(6):598–610.
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang D, Saw PE, et al. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523–545.
   PubMed Web of Science ®Google Scholar
• Alcaraz A, Hammerer P, Tubaro A, et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55(4):864–873.
   PubMed Web of Science ®Google Scholar
• Qian X, Xu D, Liu H, et al. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the alpha-adrenergic receptor antagonist. Aging Male. 2017;20(4):250–256.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu K, Nandeesha H, Dorairajan LN, et al. Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia. Aging Male. 2018;21(2):138–144.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu K, Nandeesha H, Dorairajan LN, et al. Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia. Aging Male. 2020;23(5):440–446.
   PubMed Web of Science ®Google Scholar
• Song JH, Hwang B, Chung HJ, et al. Peanut sprout extracts cultivated with fermented sawdust medium inhibits benign prostatic hyperplasia in vitro and in vivo. World J Mens Health. 2020;38(3):385–396.
   PubMedGoogle Scholar
• Fu X, Wang D, Shu T, et al. LncRNA NR2F2-AS1 positively regulates CDK4 to promote cancer cell proliferation in prostate carcinoma. Aging Male. 2020;23(5):1073–1079.
   PubMed Web of Science ®Google Scholar
• Zhao AN, Yang Z, Wang DD, et al. Disturbing NLRP3 acetylation and inflammasome assembly inhibits androgen receptor-promoted inflammatory responses and prostate cancer progression. FASEB J. 2022;36:e22602.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Y, Qin Z, et al. Correlation between prostatitis, benign prostatic hyperplasia and prostate cancer: a systematic review and meta-analysis. J Cancer. 2020;11(1):177–189.
   PubMed Web of Science ®Google Scholar
• Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163–172.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9:559.
   PubMed Web of Science ®Google Scholar
• Heberle H, Meirelles GV, da Silva FR, et al. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinf. 2015;16(1):169.
   PubMed Web of Science ®Google Scholar
• Aibar S, Gonzalez-Blas CB, Moerman T, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083–1086.
   PubMed Web of Science ®Google Scholar
• Miao YR, Zhang Q, Lei Q, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci. 2020;7(7):1902880.
   Web of Science ®Google Scholar
• Liu CJ, Hu FF, Xia MX, et al. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–3772.
   PubMed Web of Science ®Google Scholar
• Qian S, Xia J, Liu H, et al. Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer. Aging Male. 2018;21(4):231–237.
   PubMed Web of Science ®Google Scholar
• Xie Q, Liu Y, Cai T, et al. Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing. Nat Commun. 2017;8:14284.
   PubMed Web of Science ®Google Scholar
• Pala L, De Pas T, Conforti F. Boosting anticancer immunotherapy through androgen receptor blockade. Cancer Cell. 2022;40(5):455–457.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, I.S. Investigators, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559(7714):363–369.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Ratta R, Gafanov R, et al. KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(25):3291–3299.
   PubMed Web of Science ®Google Scholar
• Ke J, Chen J, Liu X. Analyzing and validating the prognostic value and immune microenvironment of clear cell renal cell carcinoma. Anim Cells Syst (Seoul). 2022;26(2):52–61.
   PubMed Web of Science ®Google Scholar
• Fisher RR, Pleskow HM, Bedingfield K, et al. Noncanonical WNT as a prognostic marker in prostate cancer: you can’t always get what you WNT. Expert Rev Mol Diagn. 2020;20(2):245–254.
   PubMed Web of Science ®Google Scholar
• Cheng L, Yang Q, Li C, et al. DDA1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle. J Cell Mol Med. 2017;21(8):1532–1544.
   PubMed Web of Science ®Google Scholar
• Capell-Hattam IM, Fenton NM, Coates HW, et al. The non catalytic protein ERG28 has a functional role in cholesterol synthesis and is coregulated transcriptionally. J Lipid Res. 2022;63(12):100295.
   PubMed Web of Science ®Google Scholar
• Fujisaki T, Saito K, Kikuchi T, et al. The prolyl hydroxylase OGFOD1 promotes cancer cell proliferation by regulating the expression of cell cycle regulators. FEBS Lett. 2022 Dec 4. doi: 10.1002/1873-3468.14547. Epub ahead of print. PMID: 36464654.
   PubMed Web of Science ®Google Scholar
• Thompson K, Mai N, Olahova M, et al. OXA1L mutations cause mitochondrial encephalopathy and a combined oxidative phosphorylation defect. EMBO Mol Med. 2018;10(11):e9060.
   PubMed Web of Science ®Google Scholar